Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 36003

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"

Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018

Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."

Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018

Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."

Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018

Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."

Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
On Sep 2018

Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."

Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata

Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
On Aug 2018

Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".

Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
On Aug 2018

Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".

Dr. Mamta Gupta
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018

Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.

Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."

Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
On May 11,2011

Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."

Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
On April 2011

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.

Dr. Anuradha
On Jan 2020

Important Notice

Original article / research
Year : 2022 | Month : May | Volume : 16 | Issue : 5 | Page : DC11 - DC13 Full Version

In-vitro Activity of Tigecycline versus Daptomycin against Clinical Isolates of Enterococcus Species

Published: May 1, 2022 | DOI:
Reena Rajan

1. Assistant Professor, Department of Microbiology, Vinayaka Mission’s Kirupananda Variyar Medical College, Salem, Tamil Nadu, India.

Correspondence Address :
Dr. Reena Rajan,
VMKVMCH Chinnaseeragapadi, Salem, Tamil Nadu, India.


Introduction: Tigecycline is a potential therapeutic agent for multidrug resistant gram positive and gram negative organisms. The clinical efficacy of synergic combination of daptomycin with betalactam antibiotics have been described against various species of Enterococcus isolates.

Aim: To detect the in-vitro activity of tigecycline and daptomycin against Enterococcus species and to compare their antimicrobial activity by Vitek 2 automated system.

Materials and Methods: This was a cross-sectional study conducted at Department of Microbiology, Vinayaka Mission’s Kirupananda Variyar (VMKV) Medical College and Hospitals, Salem, Tamil Nadu, India. Isolates of Enterococcus obtained over a period of two years from March 2016 - March 2018 from various clinical samples were identified by standard biochemical method and their antimicrobial susceptibility pattern was determined. Minimum Inhibitory Concentration (MIC) of tigecycline and daptomycin was determined by Vitek 2 automated system. Analysis of data was done by using frequency distribution and percentage.

Results: Out of 211 Enterococcus isolates studied, 23 (10.90%) isolates showed decreased susceptibility to daptomycin with MIC of ≥8 μg/mL. All isolates showed 100% susceptibility to tigecycline.

Conclusion: The present study showed potent antimicrobial activity of tigecycline against various species of Enterococcus. Decreased susceptibility to daptomycin has been observed among the study isolates. Further clinical investigations are required to know the potential benefits of these agents in therapy.


Minimum inhibitory concentration, Multidrug resistance, Vancomycin resistant Enterococcus

Antibiotic resistance among Enterococcus represents a clinical challenge due to availability of limited sources of drugs for therapy. The standard treatment regime for Enterococcal infection depends on optimised dosage and combination of antibiotics. Tigecycline has demonstrated potent in-vitro activity against a wide range of clinically important gram positive cocci, gram negative organisms, anaerobes and atypical microorganism (1). Tigecycline remains effective against Enterococcus expressing one or more vancomycin resistant determinants. Tigecycline acts on Vancomycin Resistant Enterococcus (VRE) by inhibiting 30S ribosomal subunit, thereby blocking protein synthesis. Monotherapy with tigecycline has been proven to be non inferior to other standard treatments for complicated skin and intra-abdominal infections (2),(3). The high volume distribution of tigecycline in serum makes its concentration inadequate for treating blood stream infection. Tigecycline does not require dose adjustments in patients with impaired renal function. Synergic combination of tigecycline with other antimicrobial agents such as vancomycin, gentamicin, rifampin and daptomycin have been recommended for the treatment of complex deep seated infections caused by Enterococcus (4).

Daptomycin is a novel cyclic lipopeptide antimicrobial agent that exhibits a rapid bactericidal concentration dependent action on cells through membrane lysis. Daptomycin has been shown to be a potential antimicrobial agent against Enterococcus. The major drawback for its use in VRE infection is the development of resistance during therapy. Daptomycin is not indicated for the treatment of pneumonia because of its inhibition by pulmonary surfactants (5). As per Clinical Laboratory Standards Institute (CLSI) guidelines, in-vitro susceptibility to daptomycin is defined by MIC of ≤4 μg/mL, whereas isolates with MIC of >4 μg/mL is considered as daptomycin non susceptible (6). Synergic combination of daptomycin with betalactam antibiotics have been shown to be effective against VRE species in-vitro. Beta lactams causes a reduction in cell wall positive charge by releasing lipoteichoic acid, results in destabilisation. This allows the cationic daptomycin complex to bind more effectively to cell wall (7).

There are various study reports on the efficacy of daptomycin and tigecycline against VRE (5),(7),(8),(9). However, treatment failure with daptomycin is described even in isolates with susceptible MIC for daptomycin (10). There have been only a few study data from India on the antimicrobial susceptibility of Enterococcus towards daptomycin and tigecycline (4),(11),(12). Hence, the present study was undertaken to determine the in-vitro activity of tigecycline and daptomycin against various species of Enterococcus.

Material and Methods

This cross-sectional study was done on clinical samples received at Department of Microbiology, VMKV Medical College and Hospitals, Salem, Tamil Nadu, India. A total of 15,504 clinical samples over a period of two years from March 2016-March 2018 were screened for Enterococcus. Out of which 211 samples yielded Enterococcus. This consists of 205 urine samples, three pus samples, two blood samples and one Ear swab. This study was approved by Institutional Ethical Committee (IEC) (IEC/VMMC/Microbiology/01/2015 Dated 25.03.2015).

Inclusion criteria: Clinical samples received at laboratory for routine culture and sensitivity. A colony count of >100,000 Colony Forming Unit (CFU)/mL from urine samples.

Exclusion criteria: Gram positive cocci, morphologically similar to Enterococcus, but belong to other genus were excluded based on biochemical parameters. Bacterial growth from sites which were not clinically relevant due to its commensal nature was excluded.

Sample processing: Samples were inoculated onto Blood agar and Mac Conkey agar and incubated overnight at 37oC. Isolates were further identified by gram stain morphology, catalase test and growth in bile esculin agar.

Detection of MIC by Vitek 2 automated method: Turbidometrically, controlled bacterial pure growth suspended in sterile physiological saline was used for Vitek identification and antimicrobial susceptibility testing cards. For biochemical identification of Enterococcus by Vitek 2 automated system, the following parameters were used: Growth in 6.5% Sodium chloride (NaCl), β-glucuronidase, trehalose, arginine dihydrolase, D-sorbitol, urease, raffinose, D-galactose, D-mannitol, sucrose, β-galactosidase, salicin, L-pyrrolidonylarylamidase, D-xylose, D-maltose, methyl- β-D-glycopyranoside, D-ribose, α-glucosidase, α-mannosidase, lactose, phosphatase etc. MIC break point of tigecycline and daptomycin was determined by Vitek 2 automated method.

Statistical Analysis

Data obtained was analysed by using frequency distribution and percentage.


Out of 211 Enterococcus isolates studied, 188/211 (89.09%) isolates showed decreased susceptibility to daptomycin whereas all isolates tested were susceptible to tigecycline. Majority of the isolates were obtained from patients in the age group of 41-60 years (Table/Fig 1). Of the total isolates studied from urine, pus, blood and ear swab, 197 (93.37%) were E. faecalis followed by 10 isolates of E. faecium (4.74%), 3 isolates of E. avium (1.42%) and 1 isolate of E. durans (0.47%). The most predominant isolate obtained from urine sample was E. faecalis, 192/205 (93.66%) followed by E. faecium,9/205(4.39%), E. avium,3/205(1.46%) and E. durans,1/205 (0.49%). Three (1.52%) out of 197 isolates of E. faecalis were from pus sample. Nine out of 10 E. faecium (90%) isolates were from urine sample and one (10%) isolate of E. faecium was from blood sample (Table/Fig 2).

All isolates (100%) were susceptible to tigecycline. A total of 183 (86.73%) out of 211 isolates showed susceptibility to tigecycline with MIC of ≤0.12μg/mL in all the Enterococcus species. The tigecycline MIC for 28 (13.27%) out of 211 isolates were found to be 0.25 μg/mL. 169 (85.79%) Enterococcus faecalis out of 197 isolates and 10 isolates (100%) of Enterococcus faecium showed susceptibility to tigecycline with MIC of ≤0.12 μg/mL (Table/Fig 3). A single isolate each from urine 1/205 (0.49%) and pus sample 1/3 (33.33%) was found to be resistant to penicillin, aminoglycoside, fluoroquinolone, linezolid, daptomycin and glycopeptides but showed susceptibility to tigecycline. Out of 211 isolates studied, 8 (3.79%) showed susceptibility to penicillin, 58 (27.49%) were susceptible to fluoroquinolones and 70 (33.18%) to aminoglycosides. A total of 198 (93.84%) were susceptible to teicoplanin, 207 (98.10%) to vancomycin and 206 (97.63%) showed susceptibility to linezolid.

Twenty three out of 211 isolates (10.90%) isolates showed decreased susceptibility to daptomycin with an MIC of ≥8 μg/mL and 89.10% isolates showed susceptibility to daptomycin (MIC 0.25-4 μg/mL) (Table/Fig 4).

Among the E. faecalis isolates studied from clinical samples, 174 isolates (88.32%) out of 197 showed daptomycin MIC in the susceptible range of 0.25-4 μg/mL. Twenty two E. faecalis isolates from urine and one isolate from pus sample showed decreased susceptibility to daptomycin (MIC ≥8 μg/mL) (Table/Fig 4).

Out of 23 daptomycin resistant isolates in this study, three isolates showed intermediate resistance to vancomycin with MIC of 8-16 μg/mL. Nine isolates (39.13%) showed MIC of 1-4 μg/mL to vancomycin. The vancomycin MIC for 11 daptomycin resistant isolates were ≤0.5 μg/mL. A total of 23 daptomycin resistant isolates showed MIC of teicoplanin in the range of 1-4 μg/mL. Four out of 23 isolates were resistant to linezolid with MIC of ≥8 μg/mL and 15 isolates showed linezolid MIC in the range of 1-28 μg/mL.


Tigecycline is a tetracycline-class antibacterial agent developed for the treatment of polymicrobial infections caused by multidrug resistant organisms. Tigecycline effectively penetrates body fluids and tissues and achieves therapeutic concentration (4). Isolates in current study showed 100% susceptibility to tigecycline. The tigecycline MIC break points for these isolates were in the range of 0.12 μg/mL-0.25 μg/mL.

Two (0.95%) out of 211 isolates in this study, were resistant to multiple antibiotics tested, penicillins, aminoglycosides, fluoroquinolones, linezolid, glycopeptides and daptomycin, but showed good in-vitro activity against tigecycline. Out of two isolates, one each was obtained from pus and urine sample. These isolates showed tigecycline MIC of ≤0.12 μg/mL and 0.25 μg/mL, respectively. Santimaleeworagun W et al., have reported the therapeutic potential of tigecycline (MIC susceptible breakpoint, ≤2 μg/mL) against VRE isolates from intra abdominal, skin and soft tissue infection (8).

Yemisen M et al., have reported the in-vitro activity of tigecycline against E. faecalis and E. faecium isolates with MIC of 0.12 μg/mL from clinical samples (9). In the present study, tigecycline exhibited good in-vitro activity (100% susceptibility) against E. faecalis, E. faecium, E. avium and E. durans isolated from various clinical samples.

The high in-vitro activity of tigecycline against Enterococcus have been reported by Manoharan A et al., (100%) and Veeraraghavan B et al., (60%) (4),(11). In the present study three isolates with intermediate resistance to Vancomycin with MIC of 8-16 μg/mL were also resistant to daptomycin (≥8 μg). A study conducted by Chitnis S et al., have shown the in-vitro activity of daptomycin against VRE isolates with MIC in susceptibility range of 0.19- 3 μg/mL (12).

Reduced daptomycin susceptibility and tolerance is associated with mutation in the LiaFSR three-component system which regulates cell membrane stress response in Enterococcus and for isolates with mutations to the LiaFSR system, daptomycin binding was found to be enhanced by the addition of ampicillin, ceftaroline, and beta-lactams (13),(14),(15),(16)16]. In present study, 89.10% isolates showed susceptibility to daptomycin (MIC 0.25-4 μg/mL). However, Campeau SA et al., have reported treatment failures in patients infected with daptomycin-susceptible isolates with MIC in the susceptible range 2-4 μg/mL (17).

In the present study, daptomycin resistance was observed among glycopeptide susceptible as well as glycopeptide resistant strains of Enterococcus. Tigecycline was found to be effective against isolates of Enterococcus when compared with in-vitro activity of daptomycin.


During the study period, majority of the isolates obtained were from urine samples, as the isolation rate of Enterococcus from other samples were significantly less in the study. Despite this study detects the efficacy of these drugs against various species of Enterococcus, 93.36% isolates in present study were Enterococcus faecalis. Even though the efficacy of tigecycline and daptomycin against multidrug resistant Enterococcus was proved by in-vitro method, clinical efficacy of this drugs need to be assessed by monitoring patient therapy.


Tigecycline showed good invitro activity against multidrug resistant Enterococci. Daptomycin was shown to be active against isolates of Enterococci resistant to glycopeptides and Linezolid. Isolates of Enterococcus with susceptible MIC for glycopeptides, but decreased susceptibility to daptomycin were also observed in the present study. Further studies are required to investigate the clinical efficacy of these drugs against Enterococcus.


Cercenado E. Tigecycline: A new antimicrobial agent against multiresistant bacteria. Therapy. 2007;4(3):255-70. [crossref]
Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Ghafouri MSZ, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review. Eur J Clin Microbiol Infect Dis. 2021;1-20. [crossref] [PubMed]
Cai Y, Bai N, Liu X, Liang B, Wang J, Wang R. Tigecycline: Alone or in combination? Infectious Diseases. 2016;48(7):491-502. [crossref] [PubMed]
Manoharan A, Chatterjee S, Madhan S, Mathai D. Evaluation of tigecycline activity in clinical isolates among Indian medical centers. Indian J Pathol Microbiol. 2010;53(4):734-37. [crossref] [PubMed]
Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococcus, including vancomycin intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist. 2003;9:389-93. [crossref] [PubMed]
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disc susceptibility testing; approved standard- 12th edition. CLSI document. 2015;M02A12:35(1).
Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, et al. In vitro activity of daptomycin in combination with beta-lactams, gentamycin, rifampin, and tigecycline against daptomycin-nonsusceptible Enterococci. Antimicrob Agents Chemother. 2015;59:4279-88. [crossref] [PubMed]
Santimaleeworagun W, Hemapanpairoa J, Changpradub D, Thunyaharn S. Optimizing the dosing regimens of tigecycline against vancomycin resistant enterococci in the treatment of intra-abdominal and skin and soft tissue infections. Infect Chemother. 2020;52(3):345-51. [crossref] [PubMed]
Yemisen M, Demirel A, Mete B, Kaygusuz A, Mert A, Tabak F, et al. Comparative in vitro antimicrobial activity of tigecycline against clinical isolates of vancomycin-resistant Enterococcus. Indian J Med Microbiol. 2009;27:373-74. [crossref] [PubMed]
Munita JM, Murray ME, Arias CA. Daptomycin for the treatment of bacteremia due to vancomycin resistant Enterococci. Int J Antimicrob Agents. 2014;44(5):387-95. [crossref]
Veeraraghavan B, Poojary A, Shankar C, Bari AK, Kukreja S, Thukkaram B, et al. In-vitro activity of tigecycline and comparator agents against common pathogens: Indian experience. J Infect Dev Ctries. 2019;13(3):245-50. [crossref] [PubMed]
Chitnis S, Katara G, Hemvani N, Pareek S, Chitnis DS. In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant Enterococci isolated from hospitalized cases in Central India. Indian J Med Res. 2013;137:191-96.
Wiedemann B. Test results: characterising the antimicrobial activity of daptomycin. European Society of Clinical Microbiology and Infectious Diseases. CMI. 12(Suppl. 8):9-14. [crossref]
Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphties R, et al. Ceftaroline restore Daptomycin activity against Daptomycin in susceptible vancomycin resistant Enterococcus faecium. Antimicrob Agents Chemother. 2014;58(3):1494-500. [crossref] [PubMed]
Shukla BS, Shelburne S, Reyes K, Kamboj M, Lewis JD, Rincon SL, et al. In?uence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: Is it time to change the breakpoint? Clin Infect Dis. 2016;62:1514-20. [crossref]
Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, et al. Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother. 2013;57:261-68. [crossref] [PubMed]
Campeau SA, Schuetz AN, Kohner P, Arias CA, Hemarajata P, Bard JD, et al. Variability of Daptomycin MIC values for enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests. Antimicrob agents Chemotherap. 2018;62(9):e00745-18. [crossref]

DOI and Others

DOI: 10.7860/JCDR/2022/51641.16317

Date of Submission: Jul 30, 2021
Date of Peer Review: Nov 03, 2021
Date of Acceptance: Mar 08, 2022
Date of Publishing: May 01, 2022

• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. NA

• Plagiarism X-checker: Jul 31, 2021
• Manual Googling: Mar 05, 2022
• iThenticate Software: Mar 07, 2022 (6%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)